Skip to main content
Clinical Trials/NCT02268786
NCT02268786CompletedNot Applicable

Prospective, Multi-center, Randomized Controlled Trial Comparing Pregnancy Outcomes Following Selection and Single Embryo Transfer (SET) Based on Preimplantation Genetic Screening (PGS) by Next Generation Sequencing (NGS) Versus Standard Morphological Assessment

Illumina, Inc.38 sites in 4 countries661 target enrollmentStarted: September 1, 2014Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
661
Locations
38
Primary Endpoint
Ongoing Pregnancy

Study Overview

Brief Summary

The purpose of the current study is to evaluate the effect of preimplantation genetic screening (PGS) by next generation sequencing (NGS) compared to standard morphological assessment of embryos on pregnancy rates through a randomized controlled trial (RCT). All embryos will be vitrified and a single embryo transfer (SET) will be performed with either screened or unscreened embryos depending on randomization.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Screening
Masking
Single (Participant)

Eligibility Criteria

Ages
25 Years to 40 Years (Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Patient undergoing IVF
  • •At least 2 blastocysts suitable for biopsy on day 5 or 6 of embryo development

Exclusion Criteria

  • •History of more than two prior implantation failure following IVF
  • •History of more than one miscarriage of viable pregnancy
  • •One or both partners known to be carrier(s) of a chromosomal abnormality
  • •Known genetic carrier couple and/or one or both partners carrier of a known autosomal dominant disorder
  • •Any other non-study related preimplantation genetic testing
  • •Use of donor oocytes
  • •Use of gestational carrier (surrogate or donor egg recipient).
  • •Severe oligospermia (<1,000,000 sperm/ml); Surgical Sperm Retrieval for reasons other than post-vasectomy and CAVD
  • •Low ovarian reserve with (FSH) >10 IU/L on day 2-4 of a prior menstrual cycle and/or (AMH) <7 pmol/L (or <1 ng/ml)
  • •Gender selection cycles
  • •Concurrent participation in another clinical trial

Arms & Interventions

Group A

Experimental

Intent to transfer single euploid embryo based on NGS testing (VeriSeq™ PGS) of biopsied blastocysts

Intervention: Preimplantation Genetic Screening by NGS (Other)

Group B

No Intervention

Intent to transfer single embryo based on morphological assessment according to the Gardner scoring system (no PGS)

Outcomes

Primary Outcomes

Ongoing Pregnancy

Time Frame: Gestational Age of 20 Weeks

Number of Participants with Ongoing Pregnancy at 20 Weeks Gestation

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (38)

Loading locations...

Similar Trials